Abstract
A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have